Unknown

Dataset Information

0

Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma.


ABSTRACT: Introduction:Temozolomide (TMZ) is the first-line chemotherapeutic option to treat glioma; however, its efficacy and clinical application are limited by its drug resistance properties. Polo-like kinase 1 (PLK1)-targeted therapy causes G2/M arrest and increases the sensitivity of glioma to TMZ. Therefore, to limit TMZ resistance in glioma, an angiopep-2 (A2)-modified polymeric micelle (A2PEC) embedded with TMZ and a small interfering RNA (siRNA) targeting PLK1 (siPLK1) was developed (TMZ-A2PEC/siPLK). Materials and Methods:TMZ was encapsulated by A2-PEG-PEI-PCL (A2PEC) through the hydrophobic interaction, and siPLK1 was complexed with the TMZ-A2PEC through electrostatic interaction. Th?en, an angiopep-2 (A2) modified polymeric micelle (A2PEC) embedding TMZ and siRNA targeting polo-like kinase 1 (siPLK1) was developed (TMZ-A2PEC/siPLK). Results:In vitro experiments indicated that TMZ-A2PEC/siPLK effectively enhanced the cellular uptake of TMZ and siPLK1 and resulted in significant cell apoptosis and cytotoxicity of glioma cells. In vivo experiments showed that glioma growth was inhibited, and the survival time of the animals was prolonged remarkably after TMZ-A2PEC/siPLK1 was injected via their tail vein. Discussion:The results demonstrate that the combination of TMZ and siPLK1 in A2PEC could enhance the efficacy of TMZ in treating glioma.

PROVIDER: S-EPMC7229804 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6394306 | BioStudies
2018-01-01 | S-EPMC6279590 | BioStudies
2019-01-01 | S-EPMC6927399 | BioStudies
2012-01-01 | S-EPMC3717961 | BioStudies
1000-01-01 | S-EPMC5308568 | BioStudies
1000-01-01 | S-EPMC5362526 | BioStudies
2020-01-01 | S-EPMC7086363 | BioStudies
2018-01-01 | S-EPMC6207255 | BioStudies
1000-01-01 | S-EPMC4317836 | BioStudies
2015-01-01 | S-EPMC4314441 | BioStudies